drugset / Trial / NCT00621244

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

NCT00621244

Phase 1/2 Completed 175 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies

Timeline

Start
2003-03-01
Primary completion
2009-12-03
Completion
2009-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule Oral